«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2023年06期

页码:

877-879

栏目:

短篇论著

出版日期:

2023-12-20

文章信息/Info

Title:

-

作者:

洪 俊; 张春来; 鲍黄胜

231500 庐江,安徽省庐江县人民医院肿瘤科

Author(s):

-

关键词:

小细胞肺癌;  非小细胞肺癌;  癌胚抗原;  神经元特异性烯醇化酶;  细胞角蛋白19片段

Keywords:

-

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2023.06.031

摘要:

-

Abstract:

-

参考文献/References:

1 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
3 Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis[J]. Int J Mol Sci, 2021, 22(16): 8661.
4 Potter AL, Rosenstein AL, Kiang MV, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study[J]. BMJ, 2022, 376: e069008.
5 Araujo LH, Baldotto CS, Monteiro MR, et al. Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective[J]. Future Oncol, 2021, 17(14): 1721-1733.
6 Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
7 陈 菁, 刘 旭, 杨 硕, 等. 经支气管镜针吸活检联合多标志物检测在肺癌病理分型中的应用价值[J]. 中国医科大学学报, 2019, 48(4): 342-345.
8 Jiang C, Zhao M, Hou S, et al. The indicative value of serum tumor markers for metastasis and stage of non-small cell lung cancer[J]. Cancers(Basel), 2022, 14(20): 5064.
9 Bi H, Yin L, Fang W, et al. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with clinicopathological characteristics and chemotherapeutic outcomes of lung cancer[J]. Lab Med, 2023, 54(4): 372-379.
10 Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer(NSCLC)[J]. Cancer, 2020, 126(2): 260-270.
11 国家癌症中心, 国家肿瘤质控中心肺癌质控专家委员会. 中国原发性肺癌规范诊疗质量控制指标(2022版)[J]. 中华肿瘤杂志, 2022, 44(7): 594-599.
12 Gao S, Zhang G, Lian Y, et al. Exploration and analysis of the value of tumor-marker joint detection in the pathological type of lung cancer[J]. Cell Mol Biol(Noisy-le-grand), 2020, 66(6): 93-97.
13 王 茜, 夏 睿, 董惠霞, 等. ProGRP、NSE、CEA、CYFRA21-1、SCC单独及联合检测在肺癌鉴别诊断中的价值[J]. 临床检验杂志, 2020, 38(12): 930-932.
14 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2021, 101(23): 1725-1757.
15 Yoshino K, Osumi H, Ito H, et al. Clinical usefulness of postoperative serum carcinoembryonic antigen in patients with colorectal cancer with liver metastases[J]. Ann Surg Oncol, 2022, 29(13): 8385-8393.
16 Clevers MR, Kastelijn EA, Peters B, et al. Evaluation of serum biomarker CEA and Ca-125 as immunotherapy response predictors in metastatic non-small cell lung cancer[J]. Anticancer Res, 2021, 41(2): 869-876.
17 Yoon S, Lim YK, Kim HR, et al. Establishment of reference intervals of cytokeratin 19 fragment antigen 21-1 in Korean adults[J]. Ann Lab Med, 2023, 43(1): 82-85.
18 Ouyang R, Wu S, Zhang B, et al. Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer[J]. Cancer Biomark, 2021, 32(3): 401-409.
19 Li J, Chen Y, Wang X, et al. The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer[J]. Transl Cancer Res, 2021, 10(4): 1900-1906.
20 张 婷, 向 波, 林勇平. 肿瘤标志物联合检测在肺癌辅助诊断中的预测价值[J]. 中华预防医学杂志, 2021, 55(6): 786-791.
21 Zhang T, Xiang B, Lin YP. [Predictive value of combined detection tumor markers in the diagnosis of lung cancer][J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2021, 55(6): 786-791.
22 Verttou CS, Vassiliou AG, Pratikaki M, et al. Comparative evaluation and prognostic utility of neuronal injury biomarkers in COVID-19 Patients: A prospective study[J]. Shock, 2022, 58(6): 507-513.
23 Luo H, Shen K, Sun H, et al. Clinical significance of serum neuron-specific enolase in gastric adenocarcinoma[J]. Medicine(Baltimore), 2020, 99(16):e19829.
24 Huang J, Xiao Y, Zhou Y, et al. Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study[J]. BMC Cancer, 2023, 23(1): 812.
25 Wang CF, Peng SJ, Liu RQ, et al. The combination of CA125 and NSE is useful for predicting liver metastasis of lung cancer[J]. Dis Markers, 2020, 2020: 8850873.
26 刘亚杰, 马晓波. 肿瘤标志物GSTP1、CYFRA21-1及SCC-Ag对非小细胞肺癌的预后评估价值[J]. 中国现代医学杂志, 2020, 30(14): 42-46.
27 Rumende CM, Sugianto G, Rinaldi I, et al. The association of carcinoembryonic antigen and cytokeratin-19 fragments 21-1 levels with one-year survival of advanced non-small cell lung carcinoma at cipto mangunkusumo hospital: A retrospective cohort study[J]. Acta Med Indones, 2020, 52(2): 140-146.
28 Xu FZ, Zhang YB. Correlation analysis between serum neuron-specific enolase and the detection of gene mutations in lung adenocarcinoma[J]. J Thorac Dis, 2021, 13(2): 552-561.
29 Jiao Z, Cao S, LI J, et al. Clinical associations of preoperative and postoperative serum CEA and lung cancer outcome[J]. Front Mol Biosci, 2021, 8: 686313.
30 Yuan J, Sun Y, Wang K, et al. Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction[J]. BMC Cancer, 2022, 22(1): 686.

备注/Memo

备注/Memo:

通信作者: 洪 俊, Email: 15255639388@163.com

常用功能

更新日期/Last Update: 2023-12-20